Your session is about to expire
← Back to Search
personalized ultrafractionated stereotactic ablative radiotherapy for Bladder Cancer (CIRTiN-BC Trial)
CIRTiN-BC Trial Summary
This trial is testing a new type of radiation therapy to see if it's feasible and effective for patients with bladder cancer who are unable to receive or respond to chemotherapy.
- Bladder Cancer
CIRTiN-BC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCIRTiN-BC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CIRTiN-BC Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any potential dangers associated with personalized ultrafractionated stereotactic ablative radiotherapy?
"While there is some evidence backing the safety of personalized ultrafractionated stereotactic ablative radiotherapy, it remains unproven in terms of efficacy. Consequently, our team has given it a 2."
Are there any current openings for new participants in this trial?
"That is correct, the trial is still actively recruiting patients according to the most recent update on clinicaltrials.gov from February 24th, 2022. This study was first posted on September 6th, 2021 and is looking for 27 participants total at 1 site."
How many people can take part in this experiment?
"Per the information available on clinicaltrials.gov, this trial is still recruiting patients. The listing for the study was first created on September 6th, 2021 and last updated February 24th, 2022. So far, only 27 of the needed participants have been recruited from a single site."
Share this study with friends
Copy Link
Messenger